Abstract

Muscle atrophy is a side effect of several terrestrial diseases which also affects astronauts severely in space missions due to the reduced gravity in spaceflight. An integrative graph-theoretic network-based drug repurposing methodology quantifying the interplay of key gene regulations and protein–protein interactions in muscle atrophy conditions is presented. Transcriptomic datasets from mice in spaceflight from GeneLab have been extensively mined to extract the key genes that cause muscle atrophy in organ muscle tissues such as the thymus, liver, and spleen. Top muscle atrophy gene regulators are selected by Bayesian Markov blanket method and gene–disease knowledge graph is constructed using the scalable precision medicine knowledge engine. A deep graph neural network is trained for predicting links in the network. The top ranked diseases are identified and drugs are selected for repurposing using drug bank resource. A disease drug knowledge graph is constructed and the graph neural network is trained for predicting new drugs. The results are compared with machine learning methods such as random forest, and gradient boosting classifiers. Network measure based methods shows that preferential attachment has good performance for link prediction in both the gene–disease and disease–drug graphs. The receiver operating characteristic curves, and prediction accuracies for each method show that the random walk similarity measure and deep graph neural network outperforms the other methods. Several key target genes identified by the graph neural network are associated with diseases such as cancer, diabetes, and neural disorders. The novel link prediction approach applied to the disease drug knowledge graph identifies the Monoclonal Antibodies drug therapy as suitable candidate for drug repurposing for spaceflight induced microgravity. There are a total of 21 drugs identified as possible candidates for treating muscle atrophy. Graph neural network is a promising deep learning architecture for link prediction from gene–disease, and disease–drug networks.

Highlights

  • Drug discovery is an expensive process costing an average of $1.8 million per drug

  • The gene expression values corresponding to spaceflight experiments are extracted from the excel files for the six GeneLab datasets and input to the Markov Blankets (MB) Gene Regulatory Networks (GRNs) inferencing method

  • By constructing the Disease Drug Knowledge Graph (DDKG) and applying link prediction, we have identified drugs belonging to the Monoclonal AntiBodies (MABs) family that are used for treating cancer as promising candidates for muscle atrophy in spaceflight

Read more

Summary

Introduction

Drug discovery is an expensive process costing an average of $1.8 million per drug. Most drug discovery done on Earth is under a constant environment with a gravity value of 9.81 m/s2. Spaceflight in satellites and the International Space Station (ISS) provides a gravitational acceleration of 1 × 10−6 m/s2. This is referred to as microgravity which has direct and indirect effects on an organism. Bacterial virulence and increased genetic recombination have been observed in space thereby requiring increased concentrations of antibiotics for treatment. Spaceflight environment is conducive for drug discovery, as observed in an experiment conducted on spaceflight tested a molecule Amgn0007 and sActRIIB for increasing bone mineral density in mice (Zea, 2015)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call